We are live on ! Find out more
KITE

Kite Pharma, Inc.
KITE

Delisted

KITE was delisted on the 2nd of October, 2017.

Back to rankings

62 hedge funds and large institutions have $260M invested in Kite Pharma, Inc. in 2014 Q3 according to their latest regulatory filings, with 60 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,629% more capital invested

Capital invested by funds: $6.97M → $260M (+$253M)

1,900% more first-time investments, than exits

New positions opened: 60 | Existing positions closed: 3

1,140% more funds holding

Funds holding: 5 → 62 (+57)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
62
Holders Change
+57
Holders Change %
+1,140%
% of All Funds
1.8%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
60
Increased
1
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Capital Research Global Investors
Capital Research Global Investors
California
+$59.1M
2
DM
Deerfield Management
New York
+$25M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$24.5M
4
JP Morgan Chase
JP Morgan Chase
New York
+$18.6M
5
SFM
Soros Fund Management
New York
+$16.3M

Top Sellers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.82M
2
EA
Emerald Advisers
Pennsylvania
-$1.08M
3
EMFAT
Emerald Mutual Fund Advisers Trust
Pennsylvania
-$513K
4
Citadel Advisors
Citadel Advisors
Florida
-$269K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of Montreal
51
Bank of Montreal
Ontario, Canada
$83K +$72.3K +2,921 New
STC
52
SEI Trust Company
Pennsylvania
$67K +$58.1K +2,350 New
Citigroup
53
Citigroup
New York
$47K +$40.6K +1,642 New
BG
54
BlackRock Group
United Kingdom
$41K +$35.7K +1,442 New
GSC
55
Ground Swell Capital
South Carolina
$24K +$20.8K +842 New
RA
56
Royce & Associates
New York
$23K +$19.8K +800 New
DP
57
DSAM Partners
United Kingdom
$12.7K +$11.1M +447,237 New
HI
58
Hudock Inc
Pennsylvania
$10K +$8.66K +350 New
TRCT
59
Tower Research Capital (TRC)
New York
$7K +$6.16K +249 New
BlackRock
60
BlackRock
New York
$6K +$5.52K +223 New
Manulife (Manufacturers Life Insurance)
61
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$6 +$5.07K +205 New
Alyeska Investment Group
62
Alyeska Investment Group
Illinois
– -$1.82M -63,095 Closed
EA
63
Emerald Advisers
Pennsylvania
– -$1.08M -37,250 Closed
EMFAT
64
Emerald Mutual Fund Advisers Trust
Pennsylvania
– -$513K -17,750 Closed
Deutsche Bank
65
Deutsche Bank
Germany
– +$74 +3 New
1 2
3

KITE Hedge Fund Activity: Q3 2014 in Review

62 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Kite Pharma, Inc. (KITE) for Q3 2014, worth a combined $260M — up 3,629% from $6.97M a quarter earlier.

Buyers outnumbered sellers: 60 funds opened new KITE positions and 3 closed out — a net gain of 57 holders — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Capital Research Global Investors, opening a new position worth an estimated $59.1M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $1.82M sold.

  • 62 institutional investors held Kite Pharma, Inc. (KITE) as of Q3 2014, up from 5 in Q2 2014.
  • Funds reported $260M of Kite Pharma, Inc. stock for Q3 2014, up 3,629% quarter-over-quarter.
  • 60 funds opened new Kite Pharma, Inc. positions in Q3 2014 and 3 closed out, a net change of +57 holders.
  • The largest Kite Pharma, Inc. buyer in Q3 2014 was Capital Research Global Investors, an estimated $59.1M added.
  • The largest Kite Pharma, Inc. seller in Q3 2014 was Alyeska Investment Group, an estimated $1.82M sold.

Based on aggregated 13F filings for Q3 2014.